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Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical features that include hypercalcaemia,
renal dysfunction, anaemia, and bone disease (frequently referred to by the acronymCRAB) which represent evidence of end organ
failure. Recent evidence has revealed myeloma to be a highly heterogeneous disease composed of multiple molecularly-defined
subtypes each with varying clinicopathological features and disease outcomes. The major division within myeloma is between
hyperdiploid and nonhyperdiploid subtypes. In this division, hyperdiploid myeloma is characterised by trisomies of certain odd
numbered chromosomes, namely, 3, 5, 7, 9, 11, 15, 19, and 21 whereas nonhyperdiploid myeloma is characterised by translocations
of the immunoglobulin heavy chain alleles at chromosome 14q32 with various partner chromosomes, the most important of
which being 4, 6, 11, 16, and 20. Hyperdiploid and nonhyperdiploid changes appear to represent early or even initiating mutagenic
events that are subsequently followed by secondary aberrations including copy number abnormalities, additional translocations,
mutations, and epigenetic modifications which lead to plasma cell immortalisation and disease progression. The following review
provides a comprehensive coverage of the genetic and epigenetic events contributing to the initiation and progression of multiple
myeloma and where possible these abnormalities have been linked to disease prognosis.
1. Overview of Myeloma Genetics
Myeloma is a genetically complex disease which develops
via a multistep process whereby plasma cells are driven
towards malignancy through the accumulation of genetic
“hits” over time. This multistep process permits myeloma to
have various recognisable clinical phases, distinguished by
biological parameters, along its development (Table 1). The
earliest of these phases is termed monoclonal gammopathy
of undetermined significance (MGUS) and is an indolent,
asymptomatic, premalignancy phase characterized by a small
clonal population of plasma cells within the bone marrow
of <10% [1]. MGUS has a prevalence of >5% in adults
aged over 70 and a progression risk to myeloma quantified
at 1% per year [2, 3]. Following MGUS is smouldering
multiple myeloma (SMM), another asymptomatic phase dis-
tinguished from MGUS by a greater intramedullary tumour
cell content of >10% and an average risk of progression to
myeloma of 10% per year for the first five years [4]. Next,
myeloma itself is recognised, wherebymalignant clones cause
clinically relevant end-organ damage including the features
of CRAB. The final phase is plasma cell leukemia (PCL), an
aggressive disease end-point characterised by the existence of
extramedullary clones and rapid progression to death. The
basic premise of this disease progression is that the accu-
mulation of genetic “hits” across different cellular pathways
drivesmalignant change through deregulation to the intrinsic
biology of the plasma cell. With advancements in molecular
biology, many of these disrupted genes and pathways have
now been characterised and the current challenge is therefore
how to correctly interpret these molecular findings and
develop them into clinically useful advances.
1.1. Myeloma Intraclonal Heterogeneity. Alongside aiding
the characterisation of genes and pathways disrupted in
myeloma, molecular studies have also revealed that intra-
clonal heterogeneity is a common feature of the malignancy
[5, 6]. This heterogeneity adds an extra layer of complexity to
myeloma progression as it is apparent that genetic “hits” are
not acquired in a linear fashion but rather through nonlinear
branching pathways synonymous to Darwin’s evolution of
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Table 1: Diagnostic criteria for myeloma of undetermined significance (MGUS), smouldering multiple myeloma (SMM), myeloma, and
plasma cell leukemia (PCL). Reproduced from international myeloma working group, 2003 [37].
MGUS SMM Myeloma PCL
SerumM-protein <30 g/L
SerumM-protein ≥30 g/L
AND/OR
Bone marrow clonal plasma
cells ≥10%
M-protein in serum and/or
urine.∗ No specific
concentration required Presence of ≥20% circulating
plasma cells
Absolute level of >2.0 × 109/L
Bone marrow clonal
plasma cells <10%.
If done—low level of
plasma cell infiltration in a
trephine biopsy
Confirmed clonal plasma
cells in bone marrow
Absence of end-organ disease
and symptoms
Absence of end-organ disease
and symptoms
Presence of myeloma-related
organ or tissue impairment
(ROTI)∗∗
∗1-2% of patients have no detectable M-protein in serum or urine but do have myeloma-related organ or tissue impairment (ROTI) and increased
intramedullary plasma cells; this is termed nonsecretory myeloma. ∗∗ROTI: corrected serum calcium >0.25mmol/L above the upper limit of normal or
>2.75mmol/L, creatinine >173mmol/L, Hb 2 g/dL below the lower limit of normal or <10 g/dL, lytic bone lesions or osteoporosis with compression fractures
(may be clarified by CT or MRI), symptomatic hyperviscosity, amyloidosis, recurrent bacterial infections (>2 episodes in 12 months).
Initiation Progression
MyelomaPlasma
cell
Tumour cell diversity
MGUS SMM PCL
Clonal advantage Competition and selection pressure
within bone marrow microenvironment Leukemic migration
Genetic
“hit”
Figure 1: Initiation and progression of myeloma. A postgerminal centre B cell receives a genetic “hit” which immortalizes the cell and initiates
transition to the indolent phase of monoclonal gammopathy of undetermined significance (MGUS). MGUS clones may then transition
through the other disease phases of smouldering multiple myeloma (SMM), myeloma, and plasma cell leukemia (PCL) as genetic “hits”,
which confer a survival advantage and are acquired over time. Clonal evolution develops through branching pathways whereby numerous
ecosystems composed of multiple subclones exist at each disease phase, as represented by the differing shapes. At the end of this process,
proliferative clones no longer become confined to the bone marrow and expand rapidly as a leukemic phase. At each disease phase, the
precursor clones are present only at a low level as they have been outcompeted by more advantageous clones. It should be noted that the
above figure represents an oversimplification of myeloma initiation and progression, as the process is highly complex with multiple pathways
possible at any one time (adapted fromMorgan et al., 2012 [8]).
the species [7, 8]. A model of myeloma development through
branching pathways is represented in Figure 1. This model
however is designed as an oversimplification and should be
viewed as a gross overview of disease progression as the
process is highly complexwithmultiple progression pathways
possible [8]. This analogy to Darwin’s work explains that
plasma cell clones acquire genetic lesions randomly and that
these aberrations are then selected out based on their sur-
vival advantage. Consideration of intraclonal heterogeneity is
important for disease understanding, as it is likely that the
findings from many genomic studies represent the genetic
aberrations in the predominant clonal population at the time
of sampling and that these results may not be applicable
to all subclonal populations. This has particular therapeutic
relevance, as the genes and pathways deregulated in the
predominant clonal population are unlikely to be uniform
across the many subclones allowing drug resistance and
relapse to occur through the evolution and progression of
these minority populations.
1.2. Nonhyperdiploid and Hyperdiploid Myeloma. Along the
progression from MGUS to PCL, genetic aberrations can
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Figure 2: Overexpression of cyclin D genes influence cell cycle progression at the G1/S transition point in myeloma. Increased cyclin D gene
expression through hyperdiploid or nonhyperdiploid events in myeloma facilitates activation of a cyclin-dependent kinase (CDK 4 or 6).
The respective CDK then phosphorylates Rb (retinoblastoma protein), which subsequently resides from its role inhibiting E2F transcription
factors allowing these to facilitate cell cycle progression at the G
1
/S transition. G
1
: Gap-1 phase; S: synthesis phase; G2: Gap-2 phase; M:
mitosis; P: phosphate group.
be classified as primary events, contributing to plasma cell
immortalisation, or secondary events, contributing to disease
progression. This classification facilitates the division of
myeloma into two broad groups, nonhyperdiploidy myeloma
and hyperdiploidy myeloma, based on one of two genetic
aberrations observed in the primary phase [9, 10], a dis-
tinction originally suggested by Smadja et al., supported
by the work of others, who put forward the idea of mye-
loma representing two closely related diseases [11–13]. Non-
hyperdiploidy myeloma involves the translocation (𝑡) of
immunoglobulin heavy chain alleles (IGH@) at 14q32 with
various partner chromosomes including 4, 6, 11, 16, and 20.
These primary translocations occur due to aberrant class
switch recombination (CSR) in lymph node germinal centres
and act to juxtapose the partner chromosome oncogenes
under the influence of the IGH@ enhancer region. Hyper-
diploidy myeloma is generally associated with better survival
and involves trisomies of the odd numbered chromosomes 3,
5, 7, 9, 11, 15, 19, and 21 coupled to a low prevalence of IGH@
translocations [14, 15]. Either directly, or indirectly, one
consequence of hyperdiploid and nonhyperdiploid events is
to result in deregulation of the G
1
/S cell cycle transition point
via the overexpression of cyclin D genes, an event shown to
be a key early molecular abnormality in myeloma (Figure 2)
[16]. For completion, it should be stated that exceptions to the
hyperdiploidy and nonhyperdiploidy divisions do exist and
that cases with primary translocations andmultiple trisomies
are detected in a minority.
1.3. Secondary Genetic Events and the Bone Marrow Microen-
vironment. Secondary genetic events drive disease progres-
sion and are generally found at higher frequencies in SMM,
myeloma, and PCL. These secondary events cooperate with
primary events to produce the malignant phenotype of
myeloma and include secondary translocations, copy number
variations (CNV), loss of heterozygosity (LOH), acquired
mutations, and epigenetic modifications. Coupled to the
development of these secondary events, clonal cells require
a specialised relationship with bone marrow stromal cells for
growth and survival. Studies have shown that this microenvi-
ronment interaction is highly complex, involving positive and
negative interactions between the many cell types mediated
through a variety of adhesion molecules, receptors, and
cytokines [17, 18]. Furthermore, the derangement of these
stromal-clone interactions has been shown to have important
consequences in facilitating plasma cell homing to the bone
marrow [18], promoting plasma cell immortalisation, and
helping spread to secondary bone marrow sites [19, 20]. This
stromal-clone relationship is relatively poorly understood at
present but represents an area where investigation is ongoing
and treatments are likely to be developed [21, 22].
1.4. Inherited Variation. Several studies have demonstrated
that the majority of, if not all, myeloma cases pass through
the MGUS phase [23, 24]. Therefore, in order to gain a fuller
understanding of the disease, it is important to consider the
genetic and environmental factors influencing transition to
this indolent phase. From familial studies on index cases of
myeloma, it is apparent that inherited genetic variation can
predispose to the development of MGUS as these families
have a two- to four-fold increased risk of developing the
premalignant condition [25]. By investigating these fami-
lies further, molecular epidemiology studies identified three
genetic loci with associated gene pairs (2p: DNMT3A and
DTNB, 3p: ULK4 and TRAK1, 7p: DNAH11 and CDCA7L)
which incur a modest but increased risk of developing
myeloma [26]. The complete functional role of these gene
pairs is currently unknown, although deregulation of the
proto-oncogeneMYC encoding a transcription factor which
regulates genes involved in DNA replication, cell prolifera-
tion, and apoptosis, has been implicated [26]. From these
initial studies, it is likely that more susceptibility loci will
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Figure 3:The key chromosomal translocations in myeloma. A Circos plot, with the chromosomes arranged in a clockwise direction, demon-
strating the key translocations in myeloma. The translocations are represented as lines emerging from the immunoglobulin heavy chain
(IGH@) locus on chromosome 14 to their respective partner chromosomes.The genes involved in each translocation are represented in boxes
outside the plot. All translocations represent primary events except 𝑡(8; 14) involvingMYC which is a secondary translocation.
be identified in the future and that these may be correlated
to specific myeloma subtypes. The reliable identification of
those at risk of developing myeloma would be an important
advancement as it may facilitate comprehensive diseasemon-
itoring and early disease detection. Furthermore, it could be
postulated that future targeted therapies or gene knockdown
interventions may be developed against these susceptibility
loci to restrict progression to myeloma altogether.
2. Chromosomal Translocations in Myeloma
Chromosomal translocations account for 40–50% of primary
events in myeloma and strongly influence disease phenotype
[9]. Secondary translocations, not associated with aberrant
CSR, occur later in disease and are likely to represent progres-
sion events. The key primary and secondary translocations
occurring in myeloma are highlighted in Figure 3.
2.1. 𝑡(4; 14) in Myeloma. The 𝑡(4; 14) is observed in 15% of
myeloma cases and has been associated with an adverse
prognosis in a variety of clinical settings such as those receiv-
ing high dose therapy with autologous stem cell transplant
(ASCT) [27–30]. Pathologically, 𝑡(4; 14) results in the overex-
pression of two genes, FGFR3 andMMSET, by juxtaposition
next to the IGH@ enhancers [31].The upregulation of FGFR3
results in the ectopic expression of the FGFR3 tyrosine
kinase receptor, an aberration with a currently unclear role in
myelomagenesis. Interestingly, the pathogenic role of FGFR3
is somewhat in question, as approximately 30% of 𝑡(4; 14)
tumours are imbalanced and lack FGFR3 expression due to
loss of the derivative 14 chromosome [28, 32]. Furthermore, in
these 30% lacking FGFR3 expression, the adverse prognosis
of 𝑡(4; 14) remains [28], lending support for the role of
the second gene MMSET. MMSET is overexpressed in all
𝑡(4; 14) tumours and encodes a chromatin-remodelling factor
with histone methyltransferase (HMT) activity [27]. As for
FGFR3, the exact role MMSET plays in pathogenesis is
unclear although epigenetic regulation and a role in DNA
repair have been suggested [33, 34]. In keeping with the
unifying event of cyclinD deregulation, 𝑡(4; 14)withMMSET
and/or FGFR3 overexpression have been shown to upregulate
CCND2, and in some instancesCCND1, through an unknown
mechanism [9]. It is interesting to note that despite the poor
prognosis associated with 𝑡(4; 14) a clear survival advantage
in these tumours has recently been demonstrated through
early treatment with the proteasome inhibitor bortezomib
[35, 36], with a suggestion that prolonged bortezomib treat-
ment can overcome the adverse prognosis altogether [35, 36].
This point demonstrates that futuremyelomaprognostication
is likely to be determined by the success of therapeutically
targeting high-risk lesions through a personalised approach.
2.2. 𝑡(6; 14) and 𝑡(11; 14) in Myeloma. The 𝑡(6; 14) is a rare
translocation present in 2% of myeloma patients which
results in the direct upregulation of the CCND3 gene via
juxtaposition to the IGH@ enhancers [27, 38]. 𝑡(11; 14) is
more common, occurring in approximately 17% of myeloma
patients and also directly upregulates a cyclin D gene in the
form CCND1 [27, 39]. Gene expression studies have shown
that the overexpression of CCND3 and CCND1 results in
a clustering of downstream gene expression suggesting that
activation of these two genes results in the deregulation of
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common downstream transcriptional events [27]. Due to
the seeming importance of cyclin D gene deregulation in
myeloma, cyclin D inhibitors with a variety of specificities
have shown promise targeting myeloma in vitro [40, 41], with
many of these inhibitors now entering early human trials.
Unlike 𝑡(4; 14), the overall prognostic impact of these two
translocations is neutral [42], although 𝑡(11; 14) patients do
show considerable heterogeneity and in some instances the
translocation may manifest with an aggressive phenotype
such as PCL.
2.3. 𝑡(14; 16) and 𝑡(14; 20) in Myeloma. The 𝑡(14; 16) and
𝑡(14; 20) both result in increased expression of a MAF
family oncogene and combined are identified in 5–10% of
presenting myeloma cases [27]. Specifically, 𝑡(14; 16) results
in overexpression of the MAF gene splice variant c-MAF,
a transcription factor which upregulates a number of genes
including CCND2 by binding directly to its promoter [43].
𝑡(14; 16) has been associated with a poor prognosis in a
number of clinical series [29, 44], although this concept has
recently been challenged by retrospective multivariate analy-
sis on 1003 newly diagnosedmyeloma patients which showed
𝑡(14; 16) not to be prognostic [45]. 𝑡(14; 20) is the rarest
translocation involving the IGH@ and results in upregulation
of the MAF gene paralog MAFB. Microarray studies have
demonstrated that MAFB overexpression results in a very
similar gene expression profile (GEP) to that seenwith c-MAF
[27], suggesting that common downstream targets, including
CCND2, are deregulated by each. Interestingly, 𝑡(14; 20) is
associated with a poor prognosis when present in myeloma
but correlates to long-term stable disease when found in
MGUS and SMM [46]. This suggests that the translocation
alone is not responsible for the poor prognosis but that
additional genetic events are required.
2.4. Secondary Translocations in Myeloma. As opposed to
primary translocations, secondary translocations are CSR-
independent events occurring later in disease. Further-
more, although the most frequent secondary translocation
is 𝑡(8; 14), they do not always involve the IGH@ at 14q32
with approximately 40% linking different partner genes [47].
The gene typically deregulated by secondary translocations
is MYC, the overexpression of which is linked directly to
late disease stages and indirectly to a poor prognosis via a
strong correlation to high levels of serum 𝛽
2
-microglobulin
(S𝛽
2
M) [48], an established indicator of a poor prognosis
[49]. The frequency of MYC overexpression from secondary
translocations supports its role as a progression event, as it is
infrequently witnessed in MGUS but seen in 15% of myelo-
mas and 50% of advanced disease [48, 50]. In opposition to
this, a mouse model has previously demonstrated that the
sporadic activation of a MYC transgene in germinal centre
B cells of MGUS-prone mice results in the universal devel-
opment of myeloma [51], whereas as previously discussed, an
association also exists betweenMYC deregulation and certain
genetic loci linked with myeloma susceptibility [26]. From
these conflicting findings, it appears thatMYCmay play a role
in both early and late disease phases and that further studies
are required to elucidate an exact role for the gene.
3. Copy Number Variations in Myeloma
Copy number variations result from gains and losses of DNA
and are common events in myeloma. These gains and losses
can be both focal or of an entire chromosome/chromosome
arm. In general, losses of DNA contribute to malignancy
through loss of tumour suppressor genes, whereas gains are
pathogenic through oncogene overexpression/activation.
3.1. Hyperdiploidy. Hyperdiploidy involves trisomies of the
odd numbered chromosomes and is an event witnessed in
approximately 50% of myeloma cases [14]. More common
in elderly patients and associated with a high incidence of
bone disease, hyperdiploidy confers a relatively favourable
prognosis in the majority of cases [14], a factor held par-
ticularly true in instances where amplification 5q31.3 is
concurrently present [52]. The underlying mechanism to
generate hyperdiploidy is unknown, although one hypoth-
esis, based on what is suggested to occur in hyperdiploid
acute lymphoblastic leukemia, is that a single catastrophic
mitosis results in the gain of whole chromosomes rather
than their serial accumulation over time [53]. Along with the
underlying mechanism, the consequence of hyperdiploidy
towards myelomagenesis is poorly understood. However,
alongside the known dysfunction of cyclin D genes, recent
GEP studies have demonstrated that a high proportion of
protein biosynthesis genes, specifically ribosomal protein
genes representing end-points in MYC, NF-𝜅B, and MAPK
signalling pathways, are also concurrently overexpressed in
hyperdiploid tumours [54, 55]. One explanation for this is
that these genes are overexpressed due to rapid cell pro-
liferation. This however is unlikely, as myeloma has a dis-
tinctively low proliferation rate. Instead, it is proposed that
the overexpression is driven by gene copy number increases,
with hyperdiploid cells then possessing more ribosomes and
translational initiation factors to promote myelomagenesis
through the overexpression of cellular growth genes [54].
3.2. Gain of 1q. Gain of the chromosome 1q arm (+1q) is an
event observed in 35–40% of presenting myeloma cases and
one which is frequently observed along with loss of 1p [56–
59]. +1q is associatedwith a poor prognosis in patients treated
both intensively and nonintensively and is an observation
which remains when other adverse cytogenetic lesions which
frequently coexist are removed [57, 60, 61]. Despite this
knowledge, the relevant genes on 1q are not fully explored.
One region of the chromosome armwhichhas been identified
as a frequently minimally amplified region; however, 1q21
does contain many candidate oncogenes in the form of
CKS1B, ANP32E, BCL-9, and PDZK1 [57, 60, 62]. The impor-
tance of this region is supported by the demonstration of a
strong association between +1q21 and an adverse prognosis
using both fluorescence in situ hybridization (FISH) and
GEP techniques [56, 57, 61]. Of these genes, ANP32E, a
protein phosphatise 2A inhibitor with a role in chromatin
remodelling and transcriptional regulation, is of particular
interest as it has been shown to be independently associated
with shortened survival [57]. These findings support the
importance of +1q in myeloma pathogenesis and suggest that
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patients in this group may benefit from specific inhibitors of
the candidate genes and pathways identified.
3.3. Loss of 1p. Whole arm deletion or interstitial deletions of
the 1p chromosome arm are observed in approximately 30%
ofmyeloma patients and are associated with a poor prognosis
in a range of treatment settings [57, 63, 64]. Molecular
genetics has revealed that two regions of 1p, 1p12, and 1p32.3
are particularly important in myeloma pathogenesis when
deleted. 1p12may be hemi- or homozygously deleted and con-
tains the candidate tumour suppressor gene FAM46C [5].The
function of FAM46C is unknown, although recent sequenc-
ing and homology studies have shown that its expression is
correlated to both that of ribosomal proteins and eukaryotic
initiation/elongation factors involved in protein translation
[5]. FAM46C is considered a gene of significance as it has
been shown to be frequently mutated in myeloma whilst also
being independently correlated to a poor prognosis [5, 57,
58, 63]. 1p32.3 may also be hemi- and homozygously deleted
and contains the two target genes, FAF1 and CDKN2C.
CDKN2C is a cyclin-dependent kinase 4 inhibitor involved
in negative regulation of the cell cycle, whereas FAF1 encodes
a protein involved in initiation and/or enhancement of
apoptosis through the Fas pathway. Homozygous deletion of
1p32.3 is associated with a poor prognosis in those receiving
ASCT whereas in those receiving nonintensive treatment
its prognostic impact is neutral [63]. Significant evidence
points to CDKN2C as being the influential gene lost through
homozygous 1p32.3 deletion [63, 65], although as CDKN2C
and FAF1 lie in such close proximity, the vast majority of
deletions lose both genes and therefore the importance of
FAF1 relative to CDKN2C is difficult to delineate.
3.4. Loss of Chromosome 13/13q. Chromosome 13 deletion
is observed in approximately 50% of myeloma cases and is
commonly associated with nonhyperdiploid tumours [66–
68]. In approximately 85% of cases, deletion of chromosome
13 constitutes amonosomy or loss of the q arm,whereas in the
remaining 15% various interstitial deletions occur [66, 69].
With this, the identification of key genes contributing to
myeloma pathogenesis is challenging as often a level of gene
function remains from the residual allele(s). Despite this,
molecular studies have shown that the tumour suppressor
gene RB1 is significantly underexpressed in del(13/13q) and
may therefore result in inferior negative cell cycle regulation
[57]. To establish the prognostic impact of del(13/13q) is
challenging due to its frequent association with other high-
risk lesions, such as that of 𝑡(4; 14) where it is concurrently
present in approximately 90% of cases [59].When del(13/13q)
is detected via conventional cytogenetics a link to poor
survival exists [70, 71]. However, when detected via FISH, and
in the absence of coexisting high-risk lesions, its significance
towards survival is lost [42, 72]. This finding suggests that
the historical link between del(13/13q) and a poor prognosis
is therefore a surrogate of its association with high-risk
lesions. One caveat to this statement however is that few long
term follow-up studies comparing patient outcomes with or
without these high-risk lesions have been completed whereas
several long-term studies comparing the presence or absence
of del(13/13q) do exist. In one of these studies, conducted by
Gahrton et al. [73], a 96-month followup of 357 myeloma
patients treated with either autologous transplantation or
tandem autologous/reduced intensity conditioning allogenic
transplantation (auto/RICallo) showed that whilst del(13/13q)
acted as a poor prognostic marker for those receiving autol-
ogous transplantation this factor was apparently overcome
for patients with del(13/13q) receiving auto/RICallo. This
therefore suggests that del(13/13q) may have value as a poor
prognostic marker for long-term outcomes in those receiving
autologous transplantation.
3.5. Loss of 17p. The majority of chromosome 17 deletions
are hemizygous and of the whole p arm, a genetic event
observed in approximately 10% of new myeloma cases with
this frequency increasing in later disease stages [29, 74].
The relevant gene deregulated in del(17p) is thought to be
the tumour suppressor gene TP53, as GEP has shown that
myeloma samples with monoallelic 17p deletions express
significantly less TP53 compared to nondeleted samples [57].
Furthermore, in cases without del(17p) the rate of TP53
mutation is <1%, whereas in cases with del(17p) this rises
to 25–37% [75]; a finding providing some evidence that
monoallelic 17p deletion contributes to disruption of the
remaining allele. The TP53 gene has been mapped to 17p13
and is known to function as a transcriptional regulator
influencing cell cycle arrest, DNA repair, and apoptosis in
response to DNA damage. In myeloma, del(17p) is the most
important molecular finding for prognostication as it linked
to an aggressive disease phenotype, a greater degree of
extramedullary disease, and shortened survival [29, 42, 76].
It is hypothesised that PCL is largely a consequence of TP53
dysfunction, as themajority of these cases have abnormalities
in the gene [74]. Furthermore, most, if not all, human
myeloma cell lines which survive in laboratory cell culture
have TP53 deficiency, further suggesting its importance in
extramedullary disease. Despite the consensus that TP53 is
the relevant gene disrupted in del(17p); however, it should
be stated that no direct biological evidence exists to support
this hypothesis and that further exploration of the genetic
consequences of the deletion is required.
3.6. Other Chromosomal Losses. Many other chromosomal
deletions, focal copy number losses, and regions of LOH are
seen in myeloma, and as with the deletions of 1p, 13/13q,
and 17p, the relatively high frequencies of these events in
regions containing tumour suppressor genes suggest they are
“driver” lesions contributing to myelomagenesis. Chromo-
some 11q deletion is observed in 7% of myeloma cases and
harbours the tumour suppressor genes BIRC2 and BIRC3
[57]. del(14q) is a common event found in 38% of cases
and includes the tumour suppressor gene TRAF3 [57]. 16q
deletion is another common event, seen in 35% of myeloma
cases, and contains the tumour suppressor genes CYLD and
WWOX [57]. All of these genes, except WWOX which is
implicated in apoptosis [77], are involved in the NF-𝜅B
pathway and demonstrate that activation of this signalling
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Figure 4: Signalling pathways involved in myeloma pathogenesis. The various pathways involved in myeloma pathogenesis may be stimulated
via exogenous factors, such asWnt proteins,myeloma-stromal interactions, cytokines, growth and survival factors, andmyeloma-extracellular
matrix (ECM) interactions, or the pathways may be aberrantly activated endogenously through genetic abnormalities such as activating
mutations in RAS, RAF, and NF-𝜅B genes.
pathway is important in myeloma pathogenesis [57, 78, 79].
del(12p) is another lesion of interest in myeloma, as a recent
single-nucleotide polymorphism (SNP) assay found it to be
an independent adverse prognostic marker in 192 newly
diagnosed patients [52]; a finding however not repeated in
other studies [57]. Two further common chromosomal arm
deletions frequently witnessed in myeloma are del(6q) and
del(8p), observed 33% and 19–24% of cases, respectively
[57, 80–82]. The relevance of del(6q) towards survival is as
yet not clear. For del(8p) however, it has been shown that
this aberration acts as an independently poor prognostic
factor for both progression free survival (PFS) and overall
survival (OS) [80, 81]. Furthermore, it has been shown that
the tumour necrosis factor-related apoptosis-inducing ligand
(TRALI) receptor gene is located on 8p, and that during
del(8p) a consequential downregulation of TRALI occurs
[83]. As TRALI is associated with TNF-induced apoptosis, it
is proposed that with reduced receptor expression in del(8p)
the sensitivity of tumour cells to TRAIL-medicated apoptosis
may be decreased providing an advantage for the immune
escape of malignant clones from surveillance by natural killer
cells and cytotoxic T lymphocytes [84].
4. Deregulation of Myeloma Cellular
Pathways and Processes
A range of signalling pathways are deregulated in myeloma
and contribute towards pathogenesis through associations
with proliferation, survival, apoptosis, migration, and drug
resistance (Figure 4) [85]. Other cellular processes such as
DNA repair, RNA editing, protein homeostasis, and cell
differentiation may also contribute towards myelomagenesis
through aberrant functioning.
4.1. NF-𝜅B. NF-𝜅B comprises a family of structurally related
transcription factors which are upregulated during cellular
stress to mediate gene responses. Salient to cancer, aberrant
activation of NF-𝜅B contributes to cell survival, proliferation
and adhesion pathways. In myeloma, the NF-𝜅B pathway
is constitutively active in at least 50% of cases and is likely
to represent a “driver” event due to its differing activation
frequency between MGUS and later disease phases [78, 79].
Interestingly, NF-𝜅Bmay be upregulated in both plasma cells
and surrounding bone marrow stromal cells. In these sup-
porting cells, NF-𝜅B stimulates the release of key cytokines
such as IL-6, BAFF and APRIL resulting in paracrine
stimulation and critical survival signals to malignant clones
[86, 87]. Activation of NF-𝜅B within myeloma cells occurs
through a range of mechanisms, including the inactivation
of pathway suppressors through gene deletions and/or muta-
tions, and pathway hyperactivity due to translocations and
copy number gains [78, 79]. Furthermore, a recent whole
genome sequencing (WGS) and whole exome sequencing
(WES) study expanded the possible mechanisms through
which the pathway may be activated by demonstrating 14
novel mutations/rearrangements affecting 11 NF-𝜅B pathway
genes [5]. The frequency with which NF-𝜅B is deregulated in
myeloma supports its importance in pathogenesis, although
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the prognostic impact for many of the implicated genes
are yet to be fully elucidated. As the pathway involves the
proteasome, inhibitors of this protein complex have been
developed, with evidence suggesting that tumours “addicted”
to the NF-𝜅B pathway are particularly sensitive to these
drugs [79]. Any adverse prognosis of NF-𝜅B activation may
therefore be potentially therapeutically ameliorated in the
future.
4.2. Cell Proliferation. Of the pathways highlighted in
Figure 4, three of them, the MAPK pathway, the JAK-STAT
pathway, and the PI3K pathway, are particularly implicated
in myelomagenesis through influences on cell proliferation.
4.2.1.TheMitogen Activated Protein Kinase (MAPK) Pathway.
The MAPK pathway is a highly conserved cellular signalling
cascade involved in cell differentiation, proliferation, and
survival. The pathway may be stimulated via a range of
inflammatory cytokines, such as TNF-a, IL-6, and IGF-
1, which in turn activate the downstream kinase cascades
RAS, RAF, MEK, and MAPK ultimately influencing gene
expression. Two dominant oncogenes in the MAPK pathway,
deregulated in many cancers, are NRAS and KRAS. These
genes are frequently mutated in myeloma with a combined
prevalence of 20–35% [88]. RAS mutations are likely to rep-
resent progression events as they are rarely found in MGUS
but occur more frequently in later disease [89]. Additionally,
RAS mutations are a poor prognostic marker, frequently
being associated to a more aggressive disease phenotype and
shortened survival times [88]. Recently however, it has been
suggested that KRAS, and not NRAS, is the more influential
gene impacting on prognosis [88], a finding which may have
important consequences if genetic lesions are used to define
risk. Due to the importance of RASmutations and theMAPK
pathway across many cancers, therapeutic inhibitors within
this area are a key focus of research.
Showing further importance of the MAPK pathway, a
recent study by Chapman et al. identified that seven out of
161 (4%) myeloma patients harboured a previously unob-
served mutation in the BRAF gene [5]. BRAF encodes a
serine/threonine-protein kinase in which activating muta-
tions are known to be important in many cancers including
melanoma and hairy cell leukemia [90]. This has particular
clinical relevance, as myeloma patients with BRAFmutations
may benefit from newly developed BRAF inhibitors, drugs
which in some instances have shown marked clinical activity
[91]. The premise to perform genome analysis for BRAF
mutations on 161 samples arose from an original WGS/WES
study on 38myeloma samples which revealed themutation in
one patient [5]. This highlights the advantage of WGS/WES,
in that the technique can be used as a screening tool
to identify unknown genetic aberrations across the whole
genome/exome, a benefit which may prove paramount in
identifying novel therapeutic targets and disease biomarkers.
4.2.2. The JAK-STAT Pathway. The JAK-STAT pathway is
constitutively activated in 50% of myeloma samples as well
as a proportion of surrounding bone marrow stromal cells
[92, 93]. The principal method thought to induce JAK-STAT
activation is through autocrine and paracrine stimulation
with IL-6, a cytokine shown to be important in myelomage-
nesis through the regulation of growth and survival [94, 95].
One key consequence of JAK-STAT activation is overactivity
of STAT3, a STAT family transcription factor which results
in high expression of the antiapoptotic protein Bcl-xL [94],
a protein correlated to chemoresistance in myeloma patients
[96]. With this, inhibition of STAT3 with compounds such as
curcumin, atiprimod, and the JAK2 kinase inhibitor AG490
are associated with inhibition of IL-6-induced myeloma
survival in vitro [97–99]. Furthermore, inhibition of STAT3
has been shown to sensitize the U266 myeloma cell line
to apoptosis induced through conventional chemotherapy
agents [100]. Development of STAT3 inhibitorsmay therefore
facilitate improved results with conventional chemotherapy
agents in the future.
4.2.3. The Phosphatidylinositol-3 Kinase (PI3K) Pathway. A
range of molecular signals, such as IL-6 and IGF-1, acting
on tyrosine kinase receptors can activate the PI3K pathway
leading to phosphorylation of the serine-threonine-specific
kinase AKT. AKT then subsequently activates several down-
stream targets including mTOR, GSK-3B and FKHR which
influence many processes including cell proliferation and
apoptosis resistance. Deregulation of the PI3K pathway is
thought to be important inmyeloma as phosphorylated AKT,
an indicative marker of pathway activity, is observed in
approximately 50% of cases [101]. Additionally, DEPTOR,
a positive regulator of the PI3K pathway is commonly
upregulated in myeloma, especially in those with MAF
translocations [102], further demonstrating pathway activity.
Of interest, unlike the MAPK pathway, the PI3K pathway is
rarely mutated in myeloma [5]. However, as the pathway is
known to be active, therapeutic targeting of PI3K is of interest
within myeloma research.
4.3. Cell Cycle Deregulation. Alongside the overexpression of
cyclin D genes in myeloma, the loss of function to negative
cell cycle regulatory genes also proves to be a key event
which destabilises cell cycle regulation. For example, the
downregulation of CDKN2C through del(1p), or the inacti-
vation of CDKN2A via DNA methylation changes may both
deregulate the G
1
/S transition as these genes encode cyclin-
dependent kinase inhibitors [65, 103]. Inactivation of the
tumour suppressor gene RB1, a negative cell cycle regulator,
also affects the G
1
/S transition and may occur frequently
due to monosomy 13 or infrequently due to homozygous
deletion or mutational inactivation [57]. The disruption of
RB1 is known to be a key pathological event in many cancers
and the development of anti-cancer drugs targeting cell cycle
regulators, including RB1, is a rapidly growing field.
4.4. Abnormal DNA Repair. Chromosomal instability is a
defining feature of myeloma and contributes to the perpetual
accumulation of genetic aberrations during disease progres-
sion. Despite this, consistent mutations of DNA repair genes
have not been demonstrated in the disease, with loss of TP53
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function through del(17p), found in 10% of cases, the most
common finding. Another gene of emerging importance
however is PARP1, a gene encoding the PARP1 enzyme which
contributes to repairing ssDNA breaks. A recent GEP study
has demonstrated that increased expression of PARP1 is
associatedwith shortened survival inmyeloma patients [104],
whereas another GEP study identified the gene as one of 15
which may be used as an expression signature to define high-
risk disease [105]. Investigations in this areamay prove pivotal
for myeloma, as PARP inhibitors have shown promising
activity in clinical trials [106]. This activity is especially
prominent in cancers with defective homologous recombina-
tion (HR)-mediated DNA repair mechanisms, as cells with
defects in this system are sensitized to PARP inhibitors [107].
Although not a recognised de novo finding for myeloma, it
has been shown that bortezomib can induce a HR-mediated
DNA repair defective state, a so called “BRCAness”, through
interference of BRCA1 and RAD51 recruitment to the sites of
dsDNA breaks in vitro [104]. Thus, bortezomib and a PARP
inhibitor may induce synthetic lethality and be utilised as a
future combined treatment for myeloma.
4.5. Abnormal RNA Editing. A recent study revealed that
nearly half of 38 myeloma samples contained mutations in
genes involved in RNA processing, protein translation and
the unfolded protein response (UPR) [5]. Four different
mutations of DIS3, a gene encoding an exonuclease serving
as the catalytic component of the exosome complex involved
in regulating the abundance of RNA species [108, 109], were
observed in 11% of samples [5]. The DIS3 gene has been
mapped to 13q22.1, and in three out the four mutations iden-
tified loss of function was exhibited by monoallelic mutation
coupled to deletion of the remaining allele [5]. This demon-
strates the key contribution del(13) is likely to play to DIS3
mutations and suggests another implication of this genetic
aberration alongside RB1 haploinsufficiency. Furthermore,
two of the four mutations in DIS3 have been functionally
characterised in microorganisms where they result in loss of
enzymatic activity with consequential accumulation of RNA
targets [110, 111]. As it has been shown that the exosome plays
a vital role in regulating the available pool of mRNAs for
translation [112], these mutational findings indicate that loss
of DIS3 activity may contribute to myelomagenesis through
deregulation of protein translation. Another gene, FAM46C,
implicated in del(1p) and previously discussed, gives further
support for the role of translational control in myeloma
pathogenesis, as WGS/WES found this gene to be mutated in
13% of samples [5]. This frequency supports the implication
of FAM46C in myeloma pathogenesis as recurrently mutated
genes are likely to be of biological significance.
4.6. Protein Homeostasis: The Unfolded Protein Response.
The UPR is essential for the normal functioning of plasma
cells as it serves a critical function in the efficient pro-
duction of immunoglobulin by regulating cellular responses
to unfolded/misfolded protein in the endoplasmic reticu-
lum. Of interest, sequencing has revealed mutations of the
LRRK2 gene at a frequency of 8% [5]. LRRK2 encodes
a serine-threonine kinase responsible for phosphorylating
the eukaryotic translation initiation factor 4E-binding pro-
tein 1 (EIF4EBP1), a protein which functions in regulating
protein translation. LRRK2 is predominantly known for its
association with Parkinson’s disease, where mutations in the
gene are linked to a predisposition for the condition [113,
114]. As with other neurodegenerative conditions, Parkinson’s
disease is in part characterised by a dysfunctional UPR and
abrogated protein, and as myeloma has a vastly increased rate
of immunoglobulin production [115, 116], any changes in pro-
tein homeostasis are likely to be pathogenically important. Of
related interest, sequencing data has also revealed mutations
in the UPR gene XBP1, although at a low frequency of 3%
[5]. When over-expressed in transgenic mice, a splice form
of XBP1 has been shown to induce a myeloma-like syndrome
[117], whereas in mice deficient of XBP1 B cells are able to
proliferate and construct germinal centres but are unable
to differentiate into immunoglobulin secreting plasma cells
[118].The exact role ofXBP1 in humanmyeloma pathogenesis
is unclear, although a recent study has shown that finding a
high ratio between un-spliced and spliced variants of XBP1
in myeloma samples is linked to a poor outcome and serves
as an independent prognostic factor [119].
4.7. Abnormal Plasma Cell Differentiation. One method to
establish biologically significant gain-of-function changes in
cancer genomes is to use WGS/WES to search for recurrent
identical mutations in candidate oncogenes. Utilising this
method, Chapman et al. found two myeloma patients from
38 harboured an identical mutation (K123R) in the DNA-
binding domain of the interferon regulatory factor 4 (IRF4)
[5]. As its name suggests, IRF4 is involved in regulating the
transcription of interferon’s whilst it also plays an important
role in B cell proliferation and differentiation. Interestingly,
a recent RNA-inference-based genetic screen revealed that
IRF4 function is required for myeloma cell line survival
as inhibition of the gene proved toxic to the malignant
cells [120], an in vitro finding supporting the genes role in
pathogenesis. Oneway inwhich IRF4 acts is as a transcription
factor for BLIMP1, also a transcription factor itself which
plays a key role in plasma cell differentiation. The Chapman
et al. study identified two mutations in the BLIMP1 gene
from their 38 samples, and as loss-of-function mutations in
BLIMP1 are known to occur in diffuse large B-cell lymphoma
[121], this suggests BLIMP1 mutations may be of pathogenic
importance to myeloma. Of consideration, as myeloma is
a malignancy of terminally differentiated plasma cells, the
importance of dysfunction within differentiation pathways
may be of less importance than in cancers of immature cells,
further studies are however required to investigate this.
4.8. Myeloma Bone Disease. Bone disease occurs in 80–90%
of patients with myeloma and can be either focal or diffuse
resulting in pain, pathological factures, cord compression and
hypercalcaemia. A recent GEP study aimed to identify the
molecular basis of patients presenting with bone disease in
order to elucidate whether a gene expression signature could
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identify those at high-risk of skeletal-related events after ran-
domization into one of two bisphosphonate arms [122]. The
study identified that 50 genes were significantly associated
with presenting bone disease, mostly from pathways involved
in growth factor signalling, apoptosis and transcription
regulation. The two most significantly differently expressed
genes were the Wnt pathway inhibitorsDKK1 and FRZB. The
Wnt pathway is known to be important in regulating bone
turnover andDKK1 has been shown to both inhibit osteoblast
differentiation and increase bone resorption through an
increase in the RANKL/OPG ratio [123, 124]. An antibody
against DKK1 is now being tested in clinical trials after
showing promise by improving bone disease and inhibiting
myeloma cell growth in a murine model [125]. The GEP
study was also able to make more generalised observations
of which some have been previously been reported [72, 126].
For example, bone disease is more prevalent in those with
a hyperdiploidy signature and less associated with 𝑡(4; 14)
and MAF translocations. Interestingly, this study found that
DKK1 and FRZBwere more highly expressed in hyperdiploid
tumours, providing a potential explanation for this finding.
Secondly, patients with bone disease have shorter OS com-
pared to those without [127], a finding which suggests bone
disease significantly contributes to the impaired outcome
of these patients, or, alternatively, that disease biology in
myeloma with bone disease is distinctly different.
5. Epigenetic Changes in Myeloma
The study of epigenetics is an emerging field in myeloma
and one which is demonstrating an increasing amount of
influence on pathogenesis [128]. As outlined in Figure 5, the
three main areas of epigenetic regulation include histone
modification, RNA interference and DNA methylation.
5.1. DNA Methylation. DNA Methylation changes occur at
CpG dinucleotides which are generally found at higher
frequencies in promoter regions, repeat sequences and trans-
posable elements. Changes in DNA methylation act to reg-
ulate gene expression and are known to be important in
contributing to cell development and differentiation as well
as the progression of many cancers. Myeloma genomes, as
for many other cancers, often follow a recognised pattern
of methylation represented by global DNA hypomethylation
and gene-specific hypermethylation [129]. A recent study
using a genome-wide methylation microarray built on this
knowledge to demonstrate that a marked loss methylation
occurred at the transition from MGUS to myeloma [129].
Furthermore, gene-specific hypo and hypermethylation was
demonstrated at this transition with the genes affected
involved in the cell cycle, transcriptional and cell develop-
ment pathways [129]. During progression from myeloma to
PCL, rather than finding global DNAhypomehtylation, gene-
specific hypermethylation was found in genes involved in cell
adhesion and cell signalling [129].This finding suggests these
methylation changes may contribute to destabilisation of the
stromal-clone relationship andpromotion of clonal transition
into the circulation and a proliferating leukaemic phase.
The most significant DNA methylation changes, influencing
cell survival, cell cycle progression and DNA repair, are seen
in 𝑡(4; 14) tumours [33, 130], presumably as they over-express
the MMSET gene which encodes a HMT transcription
repressor.
5.2. Histone Modification. Other genes involved in methy-
lation and chromatin modification are also deregulated in
myeloma, including KDM6A, MLL genes and HOXA9 [5].
Recent sequencing observed that HOXA9 was ubiquitously
expressed across 38 myeloma samples and hypothesised
whether this gene represented a candidate oncogene [5]. The
HOXA9 gene is primarily regulated by HMTs and encodes a
DNA-binding transcription factor which contributes to reg-
ulating gene expression, morphogenesis and differentiation.
As the majority of cases over-expressingHOXA9 in the study
exhibited bi-allelic expression, consistent with deregulation
of an upstream HMT event, genes involved in regulating
HOXA9were evaluated for mutations with findings revealing
mutations in several genes:MLL,MLL2,MLL3, andMMSET
[5]. To establish the functional importance ofHOXA9 expres-
sion in myeloma, gene knockdown studies in a range of
myeloma cell lines was performed and demonstrated that
HOXA9-depleted cells incurred a competitive disadvantage
against those with remaining HOXA9 function [5]. These
findings indicate that the expression of HOXA9 has a role in
myeloma pathogenesis and that these epigenetic changesmay
represent new therapeutic targets in myeloma.
5.3. MicroRNA Changes. MicroRNA (miRNA) genes encode
a class of small RNAs (17–25 base pairs) which function
to regulate the translation of other proteins by forming
complementary base parings to specific mRNA transcripts.
Studies have shown that miRNAs can act as both tumour
suppressors and oncogenes in a range of cancers and that
their transcriptional control is regulated by promoter methy-
lation changes [131]. A substantial amount of work has been
completed to investigate which miRNAs are differentially
expressed in myeloma [132–134], and it has been shown that
miRNA changes can deregulate genes and pathways relevant
to myeloma pathogenesis including cell cycle progression,
TP53 and MYC [135–137]. Although there is some discrep-
ancy betweenwhichmiRNAs are differentially expressed, and
when, in myeloma, the overall conclusion is that miRNA
deregulation is likely to be an important contributor to the
malignancy and that further investigation is warranted to
improve understanding and to highlight potential treatment
targets.
6. Conclusion
Myeloma is a highly heterogeneous disease and one which
may progress from an indolent, asymptomatic phase, to an
aggressive extramedullary phase as genetic “hits” are acquired
over time. The primary genetic events contributing towards
plasma cell immortalisation can be broadly divided into
a hyperdiploid group, characterised by trisomies of odd
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Figure 5:Mechanisms of epigenetic regulation. Three main forms of epigenetic modification include histone modification, RNA interference,
and DNA methylation. Histone (chromatin) modification refers to the covalent posttranslational modifications to the N-terminal tails of
the four core histone proteins; this modification is commonly acetylation/deacetylation changes at lysine residues mediated by histone
acetyltransferases (HATs) and histone deacetylases (HDACs). RNA interference is predominantly mediated through microRNAs, which
inhibit the translation of mRNA into protein. DNA methylation occurs at cytosine residues of CpG dinucleotides and acts to regulate gene
expression. Pink circle = acetyl group, purple circle = phosphate group, red circle = methyl group, blue circle = carboxyl terminus, green
circle = ubiquitin, orange circle = amino terminus, k = lysine, E = glutamic acid, S = serine. H2A, histone 2A; H2B, histone 2B; H3, histone 3;
H4, histone 4.
numbered chromosomes, and a nonhyperdiploid group,
characterised by IGH@ translocations to various partner
chromosomes; it appears that overexpression of the cyclin D
family of genes is an almost universal sequelae of primary
events. Secondary genetic events, contributing to disease pro-
gression, are complex and involve secondary translocations,
CNVs, acquired mutations, LOH, and epigenetic modifica-
tion. From the use of molecular techniques to investigate
myeloma, many of these primary and secondary events are
now well characterised, and from this characterisation, it
is apparent that disease behaviour can be correlated to the
genetic makeup of a patient’s disease. With this, it is therefore
essential that genetic research remains focused in translating
molecular characterisation into clinically useful advances.
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